<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661217</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696B2401</org_study_id>
    <secondary_id>2015-003266-87</secondary_id>
    <nct_id>NCT02661217</nct_id>
  </id_info>
  <brief_title>Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event</brief_title>
  <acronym>TRANSITION</acronym>
  <official_title>A Multicenter, Randomized, Open Label, Parallel Group Study Comparing Pre-discharge and posT-discharge tReatment Initiation With LCZ696 in heArt Failure patieNtS With Reduced ejectIon-fracTion hospItalized for an Acute decOmpensation eveNt (ADHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with&#xD;
      LCZ696 in HFrEF patients following stabilization after an ADHF episode.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2016</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization</measure>
    <time_frame>10 weeks after Randomization</time_frame>
    <description>Percentage of patients achieving and maintaining LCZ696 200 mg bid for at least 2 weeks leading to Week 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving and Maintaining Either LCZ696 100 mg and/or 200 mg Bid</measure>
    <time_frame>10 weeks after Randomization</time_frame>
    <description>Percentage of patients achieving and maintaining either LCZ696 100 mg and/or 200 mg bid for at least 2 weeks leading to Week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving and Maintaining Any Dose of LCZ696</measure>
    <time_frame>10 weeks after Randomization</time_frame>
    <description>Percentage of patients achieving any dose of LCZ696 for at least 2 weeks leading to 10 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Permanently Discontinued From Treatment</measure>
    <time_frame>10 weeks after Randomization AND 26 weeks after randomization</time_frame>
    <description>Percentage of patients permanently discontinued from LCZ696 (1) up to week 10 due to AEs, and (2) up to week 26 due to any reasons</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1002</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Pre-discharge treatment initiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-discharge treatment initiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.&#xD;
The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.</description>
    <arm_group_label>Post-discharge treatment initiation</arm_group_label>
    <arm_group_label>Pre-discharge treatment initiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients hospitalized due to acute decompensated HF episode (ADHF) as primary&#xD;
             diagnosis) and consistent Signs &amp; Symptoms&#xD;
&#xD;
          2. Diagnosis of HF New York Heart Association class II-to-IV and reduced ejection&#xD;
             fraction: Left ventricular ejection fraction ≤ 40% at Screening&#xD;
&#xD;
          3. Patients did not receive any IV vasodilators (except nitrates), and/or any IV&#xD;
             inotropic therapy from the time of presentation for ADHF to Randomization&#xD;
&#xD;
          4. Stabilized (while in the hospital) for at least 24 hours leading to Randomization.&#xD;
&#xD;
          5. Meeting one of the following criteria:&#xD;
&#xD;
               -  Patients on any dose of ACEI or ARB at screening&#xD;
&#xD;
               -  ACEI/ARB naïve patients and patients not on ACEI or ARB for at least 4 weeks&#xD;
                  before screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to the sacubitril, valsartan, or any ARBs, NEP inhibitors&#xD;
             or to any of the LCZ696 excipients.&#xD;
&#xD;
          2. Symptomatic hypotension and/or a SBP below 110 mm Hg or SBP above 180 mm Hg prior to&#xD;
             randomization&#xD;
&#xD;
          3. End stage renal disease at Screening; or estimated GFR below 30 mL/min/1.73 m2 (as&#xD;
             measured by MDRD formula at Randomization.&#xD;
&#xD;
          4. Serum potassium above 5.4 mmol/L at Randomization.&#xD;
&#xD;
          5. Known history of hereditary or idiopathic angioedema or angioedema related to previous&#xD;
             ACE inhibitor or ARB therapy&#xD;
&#xD;
          6. Severe hepatic impairment, biliary cirrhosis and cholestasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878DKF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villa Maria</city>
        <state>Cordoba</state>
        <zip>X5900JKA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405CNF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426BOR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salta</city>
        <zip>4400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucuman</city>
        <zip>T4000NIJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ronse</city>
        <zip>9600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlovy Vary</city>
        <state>Czech Republic</state>
        <zip>360 66</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liberec</city>
        <state>Czech Republic</state>
        <zip>460 63</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tabor</city>
        <state>Czech Republic</state>
        <zip>39003</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trebic</city>
        <state>Czech Republic</state>
        <zip>674 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beroun</city>
        <state>CZE</state>
        <zip>26601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <state>CZE</state>
        <zip>72880</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno Bohunice</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>JIhlava</city>
        <zip>586 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolin</city>
        <zip>280 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris cedex 10</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leverkusen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44379</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln-Nippes</city>
        <zip>50733</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Langen</city>
        <zip>63225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23569</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruesselsheim</city>
        <zip>65428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cremona</city>
        <state>CR</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Chouf</city>
        <state>LBN</state>
        <zip>1503201002</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saida</city>
        <zip>652</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alesund</city>
        <zip>NO-6026</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen</city>
        <zip>5009</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gralum</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lillehammer</city>
        <zip>2629</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90 549</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pulawy</city>
        <zip>24100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50 420</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vila Real</city>
        <state>Portuigal</state>
        <zip>5000-508</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aveiro</city>
        <zip>3814-501</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Covilha</city>
        <zip>6200-251</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guimaraes</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiria</city>
        <zip>2410-187</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1495 005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1500 650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117556</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dammam</city>
        <zip>31463</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jeddah</city>
        <zip>21499</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dunajska Streda</city>
        <state>Slovak Republic</state>
        <zip>92901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>4190</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <state>Slovak Republic</state>
        <zip>031 23</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dolny Kubin</city>
        <zip>026 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97912</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trnava</city>
        <zip>917 75</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sanlucar de Barrameda</city>
        <state>Andalucia</state>
        <zip>11540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/ Cataluny/Espanya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villamartin</city>
        <state>Cadiz</state>
        <zip>11650</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>A Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olot</city>
        <state>Girona</state>
        <zip>17800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Joenkoeping</city>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geneve 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eskisehir</city>
        <state>Meselik</state>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34304</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sivas</city>
        <zip>58140</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westcliff on Sea</city>
        <state>Essex</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashford</city>
        <state>Kent</state>
        <zip>TN24 0LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bridgend</city>
        <state>Mid Glamorgan</state>
        <zip>CF31 1RQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portadown</city>
        <state>Nothern Ireland</state>
        <zip>BT63 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunderland</city>
        <state>Tyne And Wear</state>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE 3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC14 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Swindon</city>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1498</url>
    <description>Wacther R. et al.:&#xD;
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <results_first_submitted>June 20, 2019</results_first_submitted>
  <results_first_submitted_qc>March 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2021</results_first_posted>
  <disposition_first_submitted>January 28, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 30, 2019</disposition_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute decompensated heart failure</keyword>
  <keyword>Reduced ejection fraction</keyword>
  <keyword>Pre-discharge treatment</keyword>
  <keyword>Post-discharge treatment</keyword>
  <keyword>Angiotensin receptor neprilysine inhibitor</keyword>
  <keyword>HFrEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02661217/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02661217/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomized to pre-discharge group or post-discharged group.</recruitment_details>
      <pre_assignment_details>The study consisted of 3 Epochs: the Screening Epoch (from signing of informed consent form to randomization), the treatment epoch (10 weeks following randomization), and a 16 weeks Follow-up Epoch following treatment epoch.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 Pre-discharge Treatment Initiation</title>
          <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
        </group>
        <group group_id="P2">
          <title>LCZ696 Post-discharge Treatment Initiation</title>
          <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started 10 Weeks Treatment Epoch</title>
              <participants_list>
                <participants group_id="P1" count="497"/>
                <participants group_id="P2" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 10 Weeks Treatment Epoch</title>
              <participants_list>
                <participants group_id="P1" count="460"/>
                <participants group_id="P2" count="455"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="419"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not enter follow-up epoch</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death - no study drug received</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mis-randomized (not in treatment epoch)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 Pre-discharge Treatment Initiation</title>
          <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
        </group>
        <group group_id="B2">
          <title>LCZ696 Post-discharge Treatment Initiation</title>
          <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
            <count group_id="B2" value="502"/>
            <count group_id="B3" value="1002"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="12.27"/>
                    <measurement group_id="B2" value="67.0" spread="11.67"/>
                    <measurement group_id="B3" value="66.8" spread="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="374"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="488"/>
                    <measurement group_id="B2" value="486"/>
                    <measurement group_id="B3" value="974"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization</title>
        <description>Percentage of patients achieving and maintaining LCZ696 200 mg bid for at least 2 weeks leading to Week 10</description>
        <time_frame>10 weeks after Randomization</time_frame>
        <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 Pre-discharge Treatment Initiation</title>
            <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 Post-discharge Treatment Initiation</title>
            <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization</title>
          <description>Percentage of patients achieving and maintaining LCZ696 200 mg bid for at least 2 weeks leading to Week 10</description>
          <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.896</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.786</ci_lower_limit>
            <ci_upper_limit>1.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving and Maintaining Either LCZ696 100 mg and/or 200 mg Bid</title>
        <description>Percentage of patients achieving and maintaining either LCZ696 100 mg and/or 200 mg bid for at least 2 weeks leading to Week 10</description>
        <time_frame>10 weeks after Randomization</time_frame>
        <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 Pre-discharge Treatment Initiation</title>
            <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 Post-discharge Treatment Initiation</title>
            <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving and Maintaining Either LCZ696 100 mg and/or 200 mg Bid</title>
          <description>Percentage of patients achieving and maintaining either LCZ696 100 mg and/or 200 mg bid for at least 2 weeks leading to Week 10</description>
          <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.906</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.827</ci_lower_limit>
            <ci_upper_limit>0.993</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving and Maintaining Any Dose of LCZ696</title>
        <description>Percentage of patients achieving any dose of LCZ696 for at least 2 weeks leading to 10 weeks of treatment</description>
        <time_frame>10 weeks after Randomization</time_frame>
        <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 Pre-discharge Treatment Initiation</title>
            <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 Post-discharge Treatment Initiation</title>
            <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving and Maintaining Any Dose of LCZ696</title>
          <description>Percentage of patients achieving any dose of LCZ696 for at least 2 weeks leading to 10 weeks of treatment</description>
          <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424"/>
                    <measurement group_id="O2" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.960</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.916</ci_lower_limit>
            <ci_upper_limit>1.006</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Permanently Discontinued From Treatment</title>
        <description>Percentage of patients permanently discontinued from LCZ696 (1) up to week 10 due to AEs, and (2) up to week 26 due to any reasons</description>
        <time_frame>10 weeks after Randomization AND 26 weeks after randomization</time_frame>
        <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 Pre-discharge Treatment Initiation</title>
            <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 Post-discharge Treatment Initiation</title>
            <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Permanently Discontinued From Treatment</title>
          <description>Percentage of patients permanently discontinued from LCZ696 (1) up to week 10 due to AEs, and (2) up to week 26 due to any reasons</description>
          <population>Safety Population (SAF). The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>up to week 10 due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>up to week 26 due to any reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>All Collected Deaths</title>
        <description>Pre-treatment deaths were collected from randomization until first treatment with LCZ696. The period from randomization to first treatment was up to 14 days.&#xD;
On-treatment deaths were collected from first treatment with LCZ696 until 26 weeks post randomization.</description>
        <time_frame>From randomization until 26 weeks after randomization</time_frame>
        <population>Safety Population (SAF) and randomized patients who died prior to first dose of study drug. The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 Pre-discharge Treatment Initiation</title>
            <description>Patients received first dose at any point after Randomization but no later than 12 h before discharge.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 Post-discharge Treatment Initiation</title>
            <description>Patients received first dose after discharge and up to 14 days thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>All Collected Deaths</title>
          <description>Pre-treatment deaths were collected from randomization until first treatment with LCZ696. The period from randomization to first treatment was up to 14 days.&#xD;
On-treatment deaths were collected from first treatment with LCZ696 until 26 weeks post randomization.</description>
          <population>Safety Population (SAF) and randomized patients who died prior to first dose of study drug. The SAF consisted of all randomized subjects who received at least one dose of study drug with the exception of those patients who were inadvertently randomized into the study. Subjects were analyzed according to treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="491"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-treatment deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment until 26 weeks after randomization</time_frame>
      <desc>Analysis is based on the Safety Population (SAF). It consists of all randomized patients who received at least one dose of study drug.&#xD;
Deaths not included in the SAF (i.e. did not receive study drug) are presented separately in the Participant Flow and .&#xD;
Patients are analyzed according to treatment actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-discharge</title>
          <description>Pre-discharge</description>
        </group>
        <group group_id="E2">
          <title>Post-discharge</title>
          <description>Post-discharge</description>
        </group>
        <group group_id="E3">
          <title>All Patients</title>
          <description>All patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="293" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Splenic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Catheter site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Q fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Septic phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cardiac output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ejection fraction abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Heart rate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Mediastinal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="982"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="401" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="489"/>
                <counts group_id="E3" subjects_affected="138" subjects_at_risk="982"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

